Trials / Completed
CompletedNCT02339246
Pharmacokinetic Comparison Of All FK-506 Formulations
A Steady-state Pharmacokinetic Comparison Of All FK-506 Formulations
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Veloxis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the pharmacokinetic parameters of three different formulations of tacrolimus. Eligible patients will be treated with all three formulations in a pre-defined sequence.
Detailed description
The pharmacokinetic parameters T(max), C(max) and AUC(0-24) will be compared between the three formulations Envarsus XR once daily, Astagraf XL once daily and Prograf Twice daily.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Prograf vs Envarsus XR vs Astagraf XL | prograf vs Envarsus XR vs Astagraf XL |
| DRUG | Prograf vs Astagraf XL vs Envarsus XR | Prograf vs Astagraf XL vs Envarsus XR |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2015-01-15
- Last updated
- 2016-01-18
- Results posted
- 2016-01-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02339246. Inclusion in this directory is not an endorsement.